Financial Performance - The company's operating revenue for 2019 was CNY 831,739,342.39, a decrease of 4.07% compared to 2018[16] - The net profit attributable to shareholders for 2019 was CNY 43,385,849.43, an increase of 22.50% year-over-year[16] - The net profit after deducting non-recurring gains and losses was CNY 31,332,525.26, a decrease of 20.76% from the previous year[16] - The net cash flow from operating activities reached CNY 256,227,191.99, representing a significant increase of 227.04% compared to 2018[16] - The basic earnings per share for 2019 was CNY 0.17, up 30.77% from CNY 0.13 in 2018[16] - The total assets at the end of 2019 amounted to CNY 2,250,226,095.08, an increase of 5.44% from the previous year[16] - The net assets attributable to shareholders decreased slightly by 0.99% to CNY 1,318,750,606.67 at the end of 2019[16] - The weighted average return on equity for 2019 was 3.27%, an increase of 0.91% compared to 2018[16] Revenue Breakdown - In 2019, the company's total revenue for the four quarters was approximately CNY 831 million, with the highest revenue in Q4 at CNY 257 million[18] - Revenue from proprietary drugs decreased by 26.00% to ¥208,383,232.57, accounting for 25.05% of total revenue[56] - Revenue from equipment and technology increased by 13.56% to ¥545,326,373.81, representing 65.56% of total revenue[56] - Domestic revenue fell by 25.96% to ¥286,412,968.58, while international revenue increased by 13.56% to ¥545,326,373.81[56] Research and Development - Total R&D investment for 2019 was ¥103,029,933.22, representing 12.39% of total revenue, focusing on liver disease diagnostic technology and management systems[67] - The company is focused on continuous R&D investment to develop more diverse and intelligent liver disease diagnostic products, enhancing its technological leadership[39] - The number of R&D personnel increased to 117 in 2019, accounting for 22.54% of the total workforce[68] - The capitalized R&D expenses accounted for 41.04% of total R&D investment in 2019[68] Strategic Initiatives - The company plans to continue focusing on the development of innovative medical technologies and expanding its market presence[5] - The company is transitioning its sales model from public hospitals to retail channels, aiming to enhance profit margins and control costs[27] - The company is expanding its clinical applications for FibroScan by collaborating with major hospitals and developing products tailored to different market needs[29] - The company has initiated an online medical service platform to improve patient engagement and adherence to treatment, thereby enhancing overall healthcare outcomes[30] Market Position - The company holds over 25% market share in the anti-liver fibrosis traditional Chinese medicine sector, with its main product, Fufang Bie Jia Ru Gan Pian, being a patented drug approved by the National Medical Products Administration[27] - The company's flagship product, Fufang Bie Jia Ru Gan Pian, is the first anti-liver fibrosis drug approved by the National Medical Products Administration, with a market share exceeding 25% in its category[37] - FibroScan, a non-invasive liver fibrosis detection device, has been used to diagnose millions of patients globally each year, supported by over 2,000 international publications[38] Profit Distribution - The board approved a profit distribution plan with no cash dividends or bonus shares for the year[5] - The profit distribution plan for 2019 included no cash dividends, no stock bonuses, and no capital reserve transfers[114] - The total cash dividend amount, including other methods, was ¥0.00, representing 0.00% of the total profit distribution[114] - The company has not proposed any cash dividend distribution plan despite having positive distributable profits for the reporting period[116] Corporate Governance - The governance structure of the company complies with relevant laws and regulations, ensuring equal rights for all shareholders and protecting their legal interests[200] - The company has committed to protecting the legitimate rights and interests of minority investors, with independent directors providing independent opinions on the profit distribution plan[114] - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[117] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,021, a slight decrease from 18,099 at the end of January[159] - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares, with no change during the reporting period[160] - The company does not have a controlling shareholder, as the shareholding structure is relatively dispersed[162] Employee Information - The company employed a total of 519 staff members, with 164 in the parent company and 355 in major subsidiaries[192] - The professional composition of employees includes 50 production personnel, 177 sales personnel, and 117 technical personnel[192] - The remuneration decision process involves approval from the board and submission to the shareholders' meeting[191] Social Responsibility - The company actively fulfilled its social responsibilities, providing free liver screening services to nearly 1,000 individuals[147] - The company and its subsidiaries are not classified as key pollutant dischargers by environmental protection authorities and have complied with relevant environmental laws[149]

Financial Performance - Total revenue for Q1 2020 was CNY 204,653,088.89, representing a 17.47% increase compared to CNY 174,220,949.20 in the same period last year[8]. - Net profit attributable to shareholders was CNY 10,561,335.31, up 58.45% from CNY 6,665,206.20 year-on-year[8]. - Net profit excluding non-recurring gains and losses reached CNY 10,778,547.15, a 63.42% increase from CNY 6,595,707.16 in the previous year[8]. - Basic earnings per share were CNY 0.0412, a 58.46% increase from CNY 0.0260 year-on-year[8]. - The company achieved total operating revenue of CNY 204,653,088.89, representing a year-on-year growth of 17.47%[23]. - The company reported a total comprehensive income of CNY -19,751,059.30 for the period, compared to CNY -21,955,046.96 in the previous year, indicating an improvement[57]. Cash Flow and Assets - Net cash flow from operating activities was CNY 69,587,236.96, reflecting a 46.63% increase compared to CNY 47,456,240.84 in the same period last year[8]. - As of March 31, 2020, the company's cash and cash equivalents amounted to CNY 378,633,506.70, an increase from CNY 299,079,177.17 in the previous year[48]. - The total current assets reached CNY 976,566,832.94, compared to CNY 942,101,476.58 in the same period last year, indicating a growth of approximately 3.5%[48]. - The company's total liabilities amounted to CNY 699,700,867.59, slightly up from CNY 698,663,782.17, indicating a marginal increase of about 0.15%[54]. - The total amount of cash and cash equivalents was CNY 9,589,802.89, indicating liquidity position[101]. Shareholder Information - The company reported a total of 18,099 common shareholders at the end of the reporting period[13]. - The largest shareholder, Wang Guanyi, held 11.31% of the shares, with a total of 29,754,138 shares[13]. Market and Sales Strategy - The company is transitioning its sales model for soft liver tablets from public hospitals to retail channels, enhancing market competitiveness[23]. - The company is focusing on expanding its business in the medical device, therapeutic drugs, and medical services sectors to mitigate risks associated with a single main business[26]. - The company is shifting its sales strategy for its main product from public hospitals to retail channels to stabilize gross margins[29]. Investments and Acquisitions - The investment in the acquisition of 100% equity of Echosens, a French company, was completed with a total investment of RMB 18,501.03 million, achieving 100% investment progress[37]. - The establishment of Beijing Furuizhonghe Health Technology Co., Ltd. was completed with an investment of RMB 3,100 million, also achieving 100% investment progress[37]. - The investment in the Furuizhonghe Health Technology Park was RMB 16,293.53 million, with a total investment of RMB 17,031 million, reaching 104.53% of the planned investment[37]. Research and Development - Research and development expenses for Q1 2020 were CNY 19,591,112.30, up from CNY 13,001,597.76 in the same period last year, marking an increase of approximately 50.8%[67]. - The company is prioritizing research and development in liver fibrosis diagnosis and integrating various liver disease testing methods[29]. - The company has established a technical research team in France to maintain a leading position in liver disease assessment technology[29]. Risks and Challenges - The company faces risks from increased competition in the liver disease diagnosis and treatment market, necessitating adjustments in its business structure[29]. - Cash payments related to operating activities decreased by 35% due to market activity disruptions caused by the COVID-19 pandemic[22]. Financial Adjustments - The company has made significant adjustments to its management team and structure to enhance operational efficiency and market competitiveness[23]. - The company has completed the data modeling and patent application for the FSTM project, but decided to terminate the project due to significant changes in the internal and industry environment[37].

Financial Performance - Operating revenue for the reporting period was CNY 188,998,513.21, reflecting a decline of 3.70% year-over-year[8]. - Net profit attributable to shareholders was CNY 7,788,370.63, down 24.75% compared to the same period last year[8]. - The net profit after deducting non-recurring gains and losses was CNY 7,764,935.91, a decrease of 28.84% year-over-year[8]. - Basic earnings per share were CNY 0.03, representing a decline of 25.00% compared to the previous year[8]. - The weighted average return on equity was 0.58%, down 0.15% from the previous year[8]. - Total operating revenue for Q3 2019 was CNY 188,998,513.21, a decrease of 3.2% compared to CNY 196,260,606.39 in the same period last year[65]. - Total operating costs for Q3 2019 were CNY 166,519,879.02, down 6.3% from CNY 177,771,934.72 year-on-year[65]. - Net profit for Q3 2019 reached CNY 11,886,523.50, an increase of 12.8% compared to CNY 10,537,565.43 in the previous year[68]. - The total comprehensive income for Q3 2019 was CNY 7,635,735.59, a decrease from CNY 42,638,423.41 in the previous year[72]. - The company's total comprehensive income for the third quarter was ¥730,948.49, down from ¥9,875,800.96 year-over-year[76]. - The net profit for the current period is ¥2,063,092.87, down from ¥42,628,399.93 in the previous period, reflecting a significant decline[89]. - The total comprehensive income for the current period is ¥2,063,092.87, a decrease from ¥42,628,399.93 in the previous period[91]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 1,852,343,137.92, a decrease of 13.21% compared to the previous year[8]. - Total current assets increased to ¥1,064,735,269.30 from ¥876,130,939.30, representing a growth of approximately 21.5%[47]. - Total liabilities decreased to ¥302,537,683.82 from ¥621,947,047.93, a reduction of about 51%[51]. - Total assets decreased to ¥1,852,343,137.92 from ¥2,134,224,255.98, a decline of about 13.2%[47]. - The company's total liabilities decreased to CNY 160,899,463.70 from CNY 515,625,109.54, indicating a significant reduction in debt levels[64]. - Total equity increased to CNY 889,752,565.67 from CNY 887,689,472.80, reflecting a slight growth in shareholder value[64]. - The company reported a significant reduction in short-term borrowings to ¥40,000,000.00 from ¥70,000,000.00, a decrease of approximately 42.9%[51]. - The company’s total equity represents approximately 63.2% of total liabilities and equity, indicating a strong equity position relative to its liabilities[126]. Cash Flow - Cash flow from operating activities for the year-to-date was CNY 200,049,368.29, an increase of 2,099.54% compared to the previous year[8]. - The net cash flow from operating activities was 200,049,368.29 CNY, a significant increase compared to 9,095,061.61 CNY in the previous period[98]. - Cash inflow from financing activities was 40,000,000.00 CNY, a decrease from 134,815,352.59 CNY in the previous period, leading to a net cash flow from financing activities of -34,177,022.31 CNY[100]. - The cash outflow for purchasing goods and services was 74,385,937.61 CNY, down from 113,593,377.62 CNY in the prior period[101]. - The company experienced a net increase in cash and cash equivalents of 72,750,808.43 CNY, contrasting with a decrease of 421,991,748.10 CNY in the previous period[100]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,178[12]. - The top ten shareholders held a combined 56.88% of the company's shares[13]. - The company completed a share buyback of 6,718,233 shares, accounting for 2.55% of the total share capital, with a total payment of approximately 66.99 million yuan[28]. - The company has committed to a share lock-up period of 36 months from the date of its stock listing, during which it will not transfer or entrust others to manage its shares[31]. - The company reported that its cash dividend policy is strictly implemented according to relevant regulations, ensuring that all shareholders have the opportunity to express their opinions and protect their legal rights[38]. Operational Changes - The company reported a non-operating loss of CNY 10,057,385.20 for the reporting period[8]. - The company decided to terminate the "Furu Health Technology Park" project due to the government's decision to recover the land use rights and ongoing projects[28]. - The company has made commitments to avoid competition with its subsidiaries and ensure that its controlling status remains stable[34]. - The company has not engaged in any external guarantees that violate regulations during the reporting period[40]. - The company has not reported any significant changes in net profit compared to the same period last year[38]. Investment and Development - Research and development expenses for Q3 2019 were CNY 10,786,053.10, down 24.5% from CNY 14,292,440.15 in the previous year[65]. - Research and development expenses for the year-to-date period were ¥44,016,915.97, up from ¥35,149,471.72, indicating a 25.4% increase[80]. - The company reported an investment loss of ¥370,678.98 in the third quarter, compared to a gain of ¥1,443,161.57 in the same period last year[74]. - The company reported an investment loss of ¥966,388.93, a significant decline from an investment gain of ¥3,103,207.51 in the previous period[89].

Financial Performance - Total revenue for the first half of 2019 was CNY 385,720,035.51, a decrease of 0.56% compared to CNY 387,877,244.39 in the same period last year[21]. - Net profit attributable to shareholders was CNY 16,271,846.16, down 66.26% from CNY 48,221,200.83 year-on-year[21]. - Net profit after deducting non-recurring gains and losses was CNY 26,352,666.08, a decrease of 48.09% compared to CNY 50,764,191.15 in the previous year[21]. - Basic and diluted earnings per share were both CNY 0.06, a decline of 66.67% from CNY 0.18 in the previous year[21]. - Operating profit was CNY 44,728,842.29, down 48.76% year-on-year, while net profit decreased by 54.66% to CNY 30,249,197.64[48]. - The estimated cumulative net profit for the period from the beginning of the year to the next reporting period is expected to be CNY 20.50 million, a decrease of 65.00% compared to the same period last year, which was CNY 58.57 million[100]. - Basic earnings per share are projected to be CNY 0.078, down 64.54% from CNY 0.22 in the same period last year[100]. - The expected net profit for the period from July 1 to September 30 is estimated to be CNY 7.52 million, representing a 50.00% decrease compared to CNY 10.35 million in the same period last year[100]. Cash Flow and Assets - Net cash flow from operating activities increased significantly to CNY 136,078,889.64, up 275.38% from CNY 36,251,267.16 in the same period last year[21]. - Total assets at the end of the reporting period were CNY 1,863,169,454.87, a decrease of 12.70% from CNY 2,134,224,255.98 at the end of the previous year[21]. - Current assets increased from CNY 876,130,939.30 to CNY 1,081,805,376.43, representing a growth of about 23.3%[191]. - Non-current assets decreased significantly from CNY 1,258,093,316.68 to CNY 781,364,078.44, a drop of approximately 37.9%[191]. - Cash and cash equivalents increased to CNY 74,637,631.36 from CNY 15,086,122.33, a significant increase of about 394.5%[192]. - The company’s cash and cash equivalents as of June 30, 2019, were approximately ¥292.45 million, an increase from ¥202.23 million at the end of 2018[182]. Investments and R&D - R&D investment increased by 23.36% to CNY 49,590,712.20, accounting for 12.86% of total revenue, focusing on ECHOSENS liver disease diagnostic technology[58]. - The company is focusing on product R&D to strengthen its competitive edge and meet diverse market needs, particularly in the liver disease sector[35]. - The focus of research and development is on liver fibrosis diagnosis, with plans to integrate various diagnostic methods and develop a comprehensive liver disease assessment system[106]. - The company plans to expand its business scope through continuous mergers and acquisitions in medical devices, therapeutic drugs, and medical services to enhance profitability and risk resistance[101]. Market Position and Strategy - The company experienced a decline in drug sales and gross margin due to rising raw material costs and adjustments in sales models, prompting efforts to diversify sales channels and control costs[31]. - The company is actively pursuing strategic collaborations in internet healthcare and chronic disease management, aiming to enhance service delivery and patient outcomes[37]. - The company plans to leverage its academic and technical advantages to lower barriers for medical institutions and patients, further solidifying its leadership in non-invasive liver diagnostics[35]. - The company is focusing on expanding its market presence and enhancing product development strategies[200]. - Future outlook includes potential mergers and acquisitions to strengthen market position[200]. Risk Management - There are no significant adverse risk factors affecting the company's operational, financial status, or ongoing profitability[6]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[5]. - The company faces risks from increased competition in the liver disease diagnosis and treatment market, which may pressure product sales and new product development[102]. - The company is taking measures to mitigate the impact of raw material price fluctuations, including direct procurement and price locking strategies[105]. Corporate Governance and Compliance - The company has commitments in place to avoid competition with its controlling shareholders, ensuring no direct or indirect business competition[116]. - The company has a share lock-up commitment for 36 months post-IPO, restricting the transfer of shares held by major shareholders[116]. - The company has not faced any penalties or corrective actions during the reporting period, indicating compliance with regulations[125]. - The company has not reported any major asset or equity sales during the reporting period[96]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[94][95]. Project Updates - The company has decided to terminate the health technology park project due to the recovery of state-owned land rights[74]. - The company has not achieved the planned progress and expected returns for several projects due to various reasons[78]. - The Furu Medical Center project is 45.08% complete, with no realized income due to urban planning adjustments[71]. - The liver fibrosis online diagnostic system (FSTM) project has a cumulative investment of CNY 21.61 million, representing 33.25% of the planned investment[80]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,748[159]. - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares[159]. - China National Investment Corporation holds 9.18% of the shares, totaling 24,160,000 shares[159].

Financial Performance - The company reported a total revenue of 256,334,867 RMB for the year 2018, with no cash dividends or stock bonuses distributed to shareholders [5]. - The company's operating revenue for 2018 was ¥867,029,327, representing a year-on-year increase of 5.31% compared to ¥849,675,042 in 2017 [14]. - The net profit attributable to shareholders decreased by 42.05% to ¥35,416,101 from ¥71,866,910 in 2017 [14]. - The net profit after deducting non-recurring gains and losses was ¥39,538,967, down 36.83% from ¥73,346,797 in the previous year [14]. - Cash flow from operating activities was ¥78,347,686, a decline of 40.52% compared to ¥126,160,834 in 2017 [14]. - Basic and diluted earnings per share fell by 43.48% to ¥0.13 from ¥0.27 in 2017 [14]. - Total assets at the end of 2018 were ¥2,134,224,255, a decrease of 14.99% from ¥2,502,614,050 in 2017 [15]. - The company's weighted average return on equity was 2.36%, down from 4.82% in 2017 [14]. - Operating profit was 123.30 million yuan, a decrease of 11.40% year-on-year; total profit was 116.15 million yuan, down 13.07% from the previous year [39]. Market Strategy and Product Development - The company plans to expand its market presence and enhance its product offerings, focusing on innovative diagnostic technologies like FibroScan and FibroMeter [9]. - The company’s future outlook includes a commitment to research and development in non-invasive diagnostic systems for liver fibrosis [9]. - The company aims to establish a long-term product business model and integrate liver disease diagnosis and treatment methods to promote revenue growth [29]. - The company aims to enhance its core competitiveness in diagnostic technology and product development to meet diverse market needs [95]. - The company is actively pursuing new strategies for market expansion and technological innovation to enhance its competitive edge [179]. - The company is focusing on local production in China, including the launch of domestically produced FibroScan PRO products [29]. Research and Development - Research and development (R&D) expenses for 2018 amounted to 104,705,096.95 yuan, representing 12.08% of the company's operating revenue, with a year-on-year increase of 7.33% [62]. - The number of R&D personnel decreased to 97 in 2018, making up 15.49% of the total workforce, down from 20.45% in 2017 [62]. - The company is focusing its R&D efforts on liver fibrosis diagnostics, integrating various testing methods and medical information technology tools [101]. - The company has achieved satisfactory results in its research and development efforts, including data modeling and patent applications [85]. Shareholder and Governance - The board of directors has approved a profit distribution plan based on the total shares outstanding, indicating a focus on capital preservation [5]. - The company has implemented a cash dividend policy, distributing RMB 1 per 10 shares to shareholders based on its total share capital of 263,053,100 shares as of December 31, 2017 [105]. - The company’s independent directors fulfilled their responsibilities and ensured the protection of minority shareholders' rights [106]. - The company has committed to avoiding any activities that would constitute competition with its existing and future business [112]. - The company has established a commitment to avoid any potential conflicts of interest with its controlling shareholder, ensuring the protection of shareholder interests [115]. Operational Efficiency - The company has established a real-time data transmission system for its online diagnostic services, enhancing operational efficiency [9]. - The integration of machine learning and natural language processing has improved service efficiency, reducing the time doctors spend per patient by 40% without compromising service quality [30]. - The "Love Liver Lifetime Health Management Center" provided chronic disease management services to 40,000 patients, improving service efficiency by reducing doctor-patient interaction time by 40% [42]. Legal and Compliance - The company has not issued any non-standard audit reports during the reporting period, reflecting compliance with accounting standards [118]. - The company is currently involved in a patent infringement lawsuit in Germany, with potential penalties of up to €250,000 for violations [124]. - The company reported a total economic loss compensation of RMB 30 million due to patent infringement [127]. Employee and Management Structure - The total number of employees in the company is 626, with 182 in the parent company and 444 in major subsidiaries [194]. - The professional composition includes 80 production personnel, 189 sales personnel, and 97 technical personnel [195]. - The company has a performance bonus system where bonuses typically range from 15% to 20% of monthly salary based on performance evaluations [196]. - The management team includes experienced professionals with backgrounds in finance, medicine, and technology, enhancing the company's strategic capabilities [182]. Financial Investments and Acquisitions - The company has a remaining balance of 2,192.89 million yuan in its fundraising account as of December 31, 2018 [82]. - The acquisition of the French company Echosens was completed for 18,501 million yuan, representing a 100% stake [83]. - The company has increased its stake in Echosens S.A.S. from 46.20% to 50.27%, with an additional investment cost of 11,122.00 euros [92]. Social Responsibility and Community Engagement - The company received the "2018 Best Public Welfare Practice Award" for its contributions to hepatitis prevention and control in China [146]. - The company upgraded its "Love Liver for Life" project to provide chronic liver disease family doctor services, enhancing health management and consultation services [145].

Financial Performance - Total revenue for Q1 2019 was CNY 174,220,949.20, a decrease of 0.43% compared to CNY 174,973,279.78 in the same period last year[8]. - Net profit attributable to shareholders was CNY 6,665,206.20, down 34.12% from CNY 10,116,444.70 year-on-year[8]. - Net profit excluding non-recurring gains and losses was CNY 6,595,707.16, a decrease of 34.36% compared to CNY 10,048,083.41 in the previous year[8]. - Basic earnings per share decreased by 25.00% to CNY 0.03 from CNY 0.04 in the previous year[8]. - The gross profit margin for Q1 2019 was approximately 11.9%, down from 13.6% in the same quarter last year[69]. - The total comprehensive income for Q1 2019 was CNY -12,971,227.24, compared to CNY 8,575,514.84 in Q1 2018, indicating a significant decline[76]. - The net profit for the current period is 1,019,002.81, a decrease from 7,224,727.15 in the previous period, representing a decline of approximately 86.9%[80]. - The total profit for the current period is 1,217,512.96, down from 8,652,769.87, indicating a decrease of about 85.9%[80]. Cash Flow and Liquidity - Net cash flow from operating activities increased significantly to CNY 47,456,240.84, up 1,183.36% from CNY 3,697,824.28 in the same period last year[8]. - Cash inflow from operating activities totaled 209,129,688.17, compared to 163,262,491.82 in the previous period, reflecting an increase of approximately 28.1%[86]. - Cash outflow from operating activities was 161,673,447.33, slightly up from 159,564,667.54, showing a marginal increase of about 1.3%[86]. - The cash and cash equivalents at the end of the period totaled 199,986,472.73, down from 470,045,444.55 in the previous period, indicating a decrease of approximately 57.6%[88]. - Cash flow from financing activities resulted in a net outflow of -900,209.65, compared to -192,466,523.97 in the previous period, showing an improvement[88]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,091,250,956.75, a decrease of 2.01% from CNY 2,134,224,255.98 at the end of the previous year[8]. - Total current assets decreased from ¥876,130,939.30 to ¥848,175,859.49, a decline of approximately 3.0%[52]. - Total liabilities decreased from ¥621,947,047.93 to ¥592,339,907.37, a decline of about 4.8%[55]. - Total equity decreased from ¥1,512,277,208.05 to ¥1,498,911,049.38, a decrease of approximately 0.9%[58]. - The company reported a total asset value of $2,134,224,255.98, with total liabilities amounting to $621,947,047.93, indicating a healthy asset-to-liability ratio[98]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,879[11]. - The largest shareholder, Wang Guanyi, held 11.31% of the shares, amounting to 29,754,138 shares[11]. Business Strategy and Development - The company plans to expand its business scope through acquisitions in medical devices, therapeutic drugs, and medical services[24]. - The company is focusing on developing liver fibrosis diagnostic products and integrating various liver disease testing methods[28]. - The company has initiated a plan to acquire 87.32% of Chengdu List Pharmaceutical Co., Ltd., which was disclosed on January 10, 2019[29]. - The company has decided to terminate the acquisition of List Pharmaceutical as per the board's resolution[33]. - The company plans to focus on the development and promotion of advanced diagnostic technologies through the acquisition of Echosens[40]. Research and Development - Research and development expenses increased to CNY 13,001,597.76, representing a rise of 22.4% compared to CNY 10,615,183.27 in the previous year[69]. Risks and Challenges - The company is facing risks from rising raw material prices, particularly for natural ingredients like Cordyceps, which has affected the gross margin of its main product[26]. - The company aims to mitigate raw material price fluctuations by directly purchasing from production areas and locking in prices in advance[26]. Compliance and Reporting - The first quarter report was not audited, indicating a need for caution in interpreting the financial data[105]. - The company has implemented new financial and leasing standards, which may affect future financial reporting[105].

Financial Performance - Net profit attributable to shareholders increased by 9.60% to CNY 10,349,809.37 for the current period[8] - The company reported a net profit attributable to shareholders of CNY 58,571,010.20 year-to-date, reflecting a 19.37% increase[8] - The net profit after deducting non-recurring gains and losses was CNY 10,912,072.82, up 19.76% for the current period[8] - Net profit for Q3 2018 was ¥10,537,565.43, a decrease of 31.1% from ¥15,314,773.09 in Q3 2017[40] - Net profit for the current period was ¥77.25 million, up from ¥67.08 million, reflecting an increase of 15.25%[47] Revenue and Costs - Operating revenue rose by 14.56% to CNY 196,260,606.39 for the current period[8] - Total operating revenue for Q3 2018 reached ¥196,260,606.39, an increase of 14.6% compared to ¥171,311,779.22 in the same period last year[38] - Operating costs for the same period were ¥178,954,408.77, up 19.0% from ¥150,364,749.10 year-over-year[38] - Total operating revenue for the current period reached ¥584.14 million, a slight increase from ¥583.18 million in the previous period, representing a growth of 0.16%[46] - Total operating costs decreased to ¥483.26 million from ¥497.28 million, marking a reduction of 2.04%[46] Assets and Liabilities - Total assets decreased by 12.89% to CNY 2,179,969,441.11 compared to the end of the previous year[8] - The company's current assets decreased to CNY 822,335,102.83 from CNY 1,233,449,663.04, reflecting a significant reduction of approximately 33.4%[32][34] - The company's total liabilities decreased to CNY 541,907,387.44 from CNY 570,982,246.81, a reduction of about 5.1%[34] - The total equity attributable to shareholders decreased to CNY 1,437,809,599.87 from CNY 1,502,520,319.04, reflecting a decline of approximately 4.3%[34] Cash Flow - Net cash flow from operating activities decreased by 84.01% to CNY 9,095,061.61 year-to-date[8] - The net cash flow from operating activities for Q3 2018 was ¥9,095,061.61, a decrease of 84.7% compared to ¥56,888,765.83 in the same period last year[54] - Total cash inflow from operating activities was ¥362,755,253.89, down 52.1% from ¥756,817,040.65 year-on-year[56] - The company reported a net decrease in cash and cash equivalents of ¥421,991,748.10 for the quarter, contrasting with an increase of ¥27,479,493.07 in the previous year[55] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,168[12] - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares[12] - The company distributed a cash dividend of RMB 1 per 10 shares to all shareholders based on a total share capital of 263,053,100 shares as of December 31, 2017[25] Investments and Acquisitions - The company plans to acquire 62,985,383 shares of Chengdu List Pharmaceutical Co., Ltd., representing 87.322% of the target company's total shares[20] - Long-term equity investments rose by 30% attributed to changes in the scope of consolidation[19] - The company received a cash dividend from the French subsidiary, resulting in a 496% increase in cash paid for dividends, profits, or interest[19] Research and Development - Research and development expenses increased to ¥14,292,440.15, representing a 50.5% rise from ¥9,484,351.22 in the previous year[38] - Research and development expenses increased to ¥35.15 million from ¥31.41 million, showing a rise of 11.67%[46] Other Financial Metrics - The weighted average return on net assets was 0.73%, an increase of 0.09% compared to the previous period[8] - Basic and diluted earnings per share remained stable at ¥0.04 for both Q3 2018 and Q3 2017[41] - The comprehensive income total for Q3 2018 was ¥42,638,423.41, compared to a loss of ¥3,008,599.37 in the same quarter last year[41]

Financial Performance - Total revenue for the first half of 2018 was CNY 387,877,244.39, a decrease of 5.82% compared to CNY 411,868,230.13 in the same period last year[18]. - Net profit attributable to shareholders increased by 21.71% to CNY 48,221,200.83, up from CNY 39,621,101.35 year-on-year[18]. - Net profit after deducting non-recurring gains and losses rose by 23.82% to CNY 50,764,191.15, compared to CNY 40,999,689.14 in the previous year[18]. - Net cash flow from operating activities increased by 21.76% to CNY 36,251,267.16, compared to CNY 29,772,348.21 in the same period last year[18]. - Basic earnings per share rose by 12.50% to CNY 0.18, up from CNY 0.16 in the previous year[18]. - The company achieved an operating profit of 87,290,842.49 yuan, a year-on-year increase of 27.83%[46]. - The company reported a net profit for the first half of 2018 of CNY 66,717,215.19, an increase of 28.9% compared to CNY 51,767,413.69 in the previous year[154]. Assets and Liabilities - Total assets decreased by 13.27% to CNY 2,170,641,854.70 from CNY 2,502,614,057.97 at the end of the previous year[18]. - Net assets attributable to shareholders decreased by 6.46% to CNY 1,405,421,286.21 from CNY 1,502,520,319.04 at the end of the previous year[18]. - Cash and cash equivalents decreased by 13.63% to CNY 240.84 million, accounting for 11.10% of total assets compared to 24.73% in the previous year[59]. - Accounts receivable increased by 2.81% to CNY 283.40 million, representing 13.06% of total assets[59]. - Inventory rose by 0.54% to CNY 82.26 million, making up 3.79% of total assets[59]. - Long-term equity investments increased by 1.59% to CNY 101.60 million, now 4.68% of total assets[59]. - The total liabilities slightly increased from RMB 570,982,246.81 to RMB 574,312,493.85, indicating a rise of about 0.58%[145]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company plans to launch a liver disease big data platform in Q4 2018, enhancing patient experience in chronic disease management[32]. - The company is actively expanding its sales channels by shifting from hospital sales to retail sales to mitigate the impact of bidding price limits[26]. - The company is focusing on local production in China and establishing long-term partnerships with pharmaceutical companies and hospitals[29]. - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[158]. Research and Development - Research and development investment reached 40,200,930.01 yuan, accounting for 10.36% of total revenue[50]. - The company plans to continue enhancing its R&D capabilities, focusing on liver disease diagnostic technologies and related applications[53]. - The company is focusing on the development of liver fibrosis diagnostic products, integrating various liver disease testing methods, and applying medical information technology tools[83]. - The R&D efforts will be concentrated in France, leveraging the expertise of the subsidiary Echosens in liver disease diagnostics to maintain a leading edge in the field[83]. Market Position and Competition - The company achieved a year-on-year sales revenue growth of 15.67% for its main product, the Compound Turtle Shell Soft Liver Tablets, during the reporting period[26]. - The market share of the Compound Turtle Shell Soft Liver Tablets in the anti-liver fibrosis traditional Chinese medicine sector exceeds 25%[26]. - The company anticipates increased competition in the liver disease diagnosis and treatment market due to rising health awareness and improved medical insurance systems[81]. - The company faces risks from a single main business focus, primarily in liver fibrosis treatment drugs and diagnostic equipment[80]. Corporate Governance and Compliance - The financial statements were prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status and operating results[190]. - The financial statements were approved by the board of directors on August 29, 2018[186]. - The company confirmed that there were no penalties or rectification situations during the reporting period[96]. - The company is actively pursuing legal actions to protect its intellectual property rights[94]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,766[126]. - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares[127]. - The total number of restricted shares at the end of the period was 35,086,378 shares, after accounting for the unlocked shares[124]. - The company completed the unlocking of 96,000 restricted stocks, accounting for 0.0365% of the total share capital, as part of its stock incentive plan[98].

Financial Performance - Total revenue for Q1 2018 reached ¥174,973,279.78, an increase of 13.28% compared to ¥154,464,955.00 in the same period last year[9] - Net profit attributable to shareholders was ¥10,116,444.70, representing a growth of 19.24% from ¥8,483,748.91 year-on-year[9] - Basic earnings per share rose to ¥0.038, an increase of 8.57% compared to ¥0.035 in the same period last year[9] - The company's net profit attributable to shareholders increased by 19.24% year-on-year, contributing to overall performance growth[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 10,048,083.41, up by 14.68% year-on-year[26] - The company reported a decrease in expenses compared to the previous year, contributing to improved profitability[26] - The net profit for Q1 2018 reached CNY 16,864,501.86, compared to CNY 14,214,539.65 in Q1 2017, indicating a year-over-year increase of about 18.6%[50] - The gross profit margin improved, with operating profit for Q1 2018 at CNY 24,522,108.42, up from CNY 21,032,931.05 in Q1 2017, reflecting a growth of approximately 16.4%[50] Cash Flow - Net cash flow from operating activities improved significantly to ¥3,697,824.28, a 226.01% increase from a negative cash flow of ¥2,934,498.99 in the previous year[9] - The total cash inflow from operating activities was ¥163,262,491.82, while cash outflow was ¥159,564,667.54, resulting in a net cash flow of ¥3,697,824.28[58] - The company reported a net increase in cash and cash equivalents of ¥99,403,082.01 for the quarter, contrasting with a decrease of ¥46,419,101.70 in the previous year[63] - The ending balance of cash and cash equivalents was ¥174,681,890.94, compared to ¥118,170,253.45 at the end of Q1 2017[63] - Cash inflow from financing activities totaled ¥104,962,415.37, up from ¥51,600,000.00 in the same period last year, leading to a net cash outflow of ¥51,700,880.41[59] Assets and Liabilities - Total assets decreased by 6.65% to ¥2,336,268,047.33 from ¥2,502,614,057.97 at the end of the previous year[9] - Current liabilities increased to CNY 335,213,316.21 from CNY 217,952,154.52, marking a significant rise of 53.6%[43] - The company's total liabilities increased to CNY 687,187,990.28 from CNY 570,982,246.81, reflecting a growth of 20.5%[43] - The total equity attributable to shareholders decreased to CNY 1,399,945,149.92 from CNY 1,502,520,319.04, a decline of 6.8%[44] Strategic Initiatives - The company plans to expand its business scope through acquisitions in medical devices, therapeutic drugs, and medical services to enhance profitability and risk resistance[11] - The company aims to accelerate its strategic transformation and diversify its product offerings to mitigate risks associated with industry competition and policy changes[12] - The company is focusing on developing diagnostic products for liver fibrosis, integrating various liver disease detection methods, and utilizing medical information technology tools[14] - The company plans to continue expanding its market presence and product development, focusing on internal R&D advancements[25] Risks and Challenges - The company faces risks from rising raw material prices, particularly for Cordyceps, which may impact product gross margins[13] - The company is currently facing important risk factors that may adversely affect future operations, as detailed in the report[26] - The company has implemented measures to address major difficulties in operations as outlined in the report[26] Shareholder Information - The top ten shareholders include Wang Guanyi with 11.31% and China National Investment & Guaranty Corporation with 9.18% of shares[16] - The company has committed to avoiding any business competition with its wholly-owned and holding enterprises, ensuring no new investments in similar business operations[31] - The company has fulfilled its commitment to avoid transferring or entrusting the management of its shares for 36 months post-IPO[30] - The company has confirmed that it will not seek to become the controlling shareholder of Furu Medical Technology Co., Ltd. in any form[30] - The company has ensured that its shareholders will not engage in activities that may harm the interests of Furu Medical Technology Co., Ltd. and its other shareholders[31] Investment Activities - Short-term borrowings rose by 134% to CNY 175,490,030.96 due to temporary funding for acquiring shares in Echosens, a French company[24] - Investment cash payments surged by 1336% to CNY 157,955,043.56 for acquiring part of Echosens' equity during the reporting period[24] - The company is in the process of acquiring shares from the shareholders of Echosens, with a total of 12,434 shares being acquired, resulting in a 50.39% ownership stake in Echosens[28] - The total amount raised from the IPO was RMB 505.24 million, with RMB 378.95 million being excess funds[34] - The company used RMB 184.13 million of excess funds to acquire 100% of Echosens in France, completing the acquisition by June 29, 2011[34]

Financial Performance - The company's operating revenue for 2017 was ¥849,675,042.33, representing a 2.74% increase compared to ¥826,987,166.98 in 2016[17] - The net profit attributable to shareholders for 2017 was ¥71,866,910.82, a decrease of 40.63% from ¥121,047,929.99 in 2016[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥73,346,797.89, down 38.82% from ¥119,889,414.85 in the previous year[17] - The net cash flow from operating activities was ¥126,160,834.06, a decline of 15.24% compared to ¥148,843,876.72 in 2016[17] - Basic earnings per share for 2017 were ¥0.27, a decrease of 41.30% from ¥0.46 in 2016[17] - The total assets at the end of 2017 amounted to ¥2,502,614,057.97, reflecting a 3.99% increase from ¥2,406,635,582.65 at the end of 2016[17] - The net assets attributable to shareholders at the end of 2017 were ¥1,502,520,319.04, up 2.75% from ¥1,462,369,062.35 in 2016[17] - The weighted average return on equity for 2017 was 5.16%, down from 8.65% in 2016[17] - The company reported a total non-recurring loss of CNY 1,479,887.07 in 2017, compared to a gain of CNY 1,158,515.14 in 2016[23] - The company achieved total revenue of 849.675 million yuan in 2017, representing a year-on-year growth of 2.74%[43] - The company reported a significant increase in financial expenses due to exchange losses from USD to EUR, with a change of -1,620.70%[68] - The total revenue for the year 2017 was approximately 34.7 million, showing a significant increase compared to previous years[163] - The company reported a net profit of 701,300, indicating a strong financial performance[163] Dividend Policy - The company plans to distribute a cash dividend of ¥1.00 per 10 shares to all shareholders based on the total share capital as of December 31, 2017[6] - The company announced a cash dividend of CNY 1.00 per 10 shares, totaling CNY 26,305,310.00 for the reporting period, which represents 100% of the distributable profit[106] - The total distributable profit for the year was CNY 382,858,308.40, indicating a strong profitability position[106] - The cash dividend payout ratio for 2017 was 36.60% of the net profit attributable to ordinary shareholders, compared to 21.75% in 2016 and 28.71% in 2015[109] - The company has consistently maintained a cash dividend distribution of CNY 1.00 per 10 shares for the past three years[107] - The cash dividend represents the entirety of the profit distribution for the year, reflecting a commitment to returning value to shareholders[106] Research and Development - The company invested CNY 86,113,094.43 in R&D for diagnostic equipment, representing 10.13% of its operating revenue[28] - Research and development investment increased to 86,113,094.43, representing 10.13% of operating revenue, up from 7.99% in 2016[69] - The number of research and development personnel rose to 133, accounting for 20.45% of the workforce, compared to 19.05% in 2016[70] - The company is focusing on new technology research and development to improve its product offerings[170] Market Expansion and Strategy - The company plans to expand its sales channels and strengthen cooperation with hospitals and retail channels to stabilize and grow sales revenue[26] - The company has actively pursued partnerships and joint ventures to introduce advanced diagnostic technologies into the Chinese market[34] - The company is actively expanding its medical device market in North America, Asia-Pacific, and China, adjusting strategies based on local conditions[49] - The company plans to enhance cooperation with hospitals and expand retail channels to adapt to pharmaceutical cost control policies[50] - The company is expanding its market presence, targeting a 30% increase in market share in the next two years[178] - The company plans to enter international markets, with an initial investment of 100 million RMB allocated for expansion efforts[178] Product Performance - The sales revenue of Echosens in 2017 was €65,065,625, reflecting a year-on-year growth of 25.41%[28] - Sales revenue from diagnostic instruments increased by 26.18% year-on-year, while pharmaceutical sales revenue declined due to bidding price limits and sales model adjustments[43] - The company achieved sales of 853 FibroScan devices in 2017, representing a year-on-year growth of 26.18%[49] - Revenue from medical devices accounted for 58.09% of total revenue, with a year-on-year increase of 33.75%[56] - The company's proprietary drug sales decreased by 33.87%, contributing €232,000,340.09 to total revenue[58] - The market share of the proprietary drug, Fufang Bie Jia Ru Gan Pian, exceeds 25%, making it the leading product in the anti-liver fibrosis category[50] Operational Efficiency - The company has upgraded its mobile medical service platform to enhance patient-doctor interactions and streamline appointment and consultation processes[46] - The company is focused on enhancing operational efficiency and expanding its service capabilities[167] - Operational efficiency improvements are expected to reduce costs by 5%, translating to savings of approximately 75 million RMB annually[178] Governance and Compliance - The company has established a comprehensive governance structure, including various rules and regulations to ensure compliance and promote healthy development[190] - There are no significant discrepancies between the company's governance practices and the regulatory requirements set by the China Securities Regulatory Commission[191] - The company operates independently from its major shareholders in terms of business, assets, personnel, institutions, and finances, maintaining a self-sufficient operational capability[192] Shareholder Structure - The company has a diversified shareholder structure, with no other shareholders holding more than 10% of the shares[157] - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares, with a recent increase of 22,315,603 shares[152] - The company’s stock structure remains stable, with no significant impact on asset and liability structure from the repurchase[150] Employee Management - The total remuneration for the board of directors, supervisors, and senior management in 2017 was 4.6994 million CNY[179] - The company has a total of 649 employees, with 222 in sales, 133 in technical roles, and 90 in production[182] - The remuneration for the chairman was 567,500 CNY, while the total remuneration for the general manager was 758,700 CNY[180] - The company has established a performance-based bonus system, with performance bonuses typically ranging from 15% to 20% of monthly salaries[184] Future Outlook - Future guidance indicates a positive outlook for revenue growth and profitability in the upcoming fiscal periods[163] - The company aims to explore potential mergers and acquisitions to strengthen its market position[167]